小剂量人重组红细胞生成素不同给药途径治疗慢性肾衰贫血临床观察

目的:观察小剂量人类重组红细胞生成素 (rhu -Epo)皮下注射与静脉注射两种给药途径对慢性肾衰贫血的疗效。探索更为有效、安全、经济的给药途径。方法 :用随机数字表法将20例慢性肾功能衰竭贫血病人分为两组 :分别采用皮下注射 (治疗组 )与静脉注射 (对照组 )两种给药途径 ,比较两种不同给药途径疗效的差异。结果 :两组病人RBC、Hb、Hct均有明显上升 ,与治疗前比较差别均有很显著性 (P<0.01)。6周内两组之间比较差别无显著性 (P>0.05)。皮下注射组治疗后2周与6周RBC、Hb、Hct差别有很显著性 (P<0.01)。两组均有血压增高。结论 :小剂量rhu -Epo皮下注射与静脉注射均能有效改善慢性肾衰病人的贫血,两种给药途径相比较,皮下注射更安全、经济、适用。

Observation on curative effect of low dose recombinant human erythopoietin in different routesof drug administration for treating anemia of chronic renal failure

Objective:To observe the curative effect of low dose recombinant human erythopoietin(RHE) by subsutaneous injection or intravenous injection for treating anemia of chronic renal failure,so as to explore a more effective,safe and economic rout of drug administration.Methods:With random control experiment,20 cases with anemia of chronic renal failure were randomly divided into two groups by random digital table,which were adopted by subcutaneous injection(experiment group) or intravenous injection(control group) respectively.The difference of curative effect in both routes of drug administration was compared.Results:RBC,Hb and Hct in both groups were obviously increased compared with those before treatment(P<0.01),but no significant difference was found between two groups within 6 weeks after treatment(P>0.05).The differences of RBC,Hb and Hct in the subcutaneous injection group were significant between 2 weeks and 6 weeks after treatment(P<0.01).The blood pressure in both groups was increased.Conclusion:Both subcutaneous injection and intravenous injection are effective for improving the anemia of chronic renal failure.Subcutaneous injection is more safe,economic and practical compared with the intravenous injection.